Canada - English - Health Canada

pharmascience inc - prednisolone (prednisolone sodium phosphate) - solution - 5mg - prednisolone (prednisolone sodium phosphate) 5mg - adrenals

Canada - English - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 40mg - methylprednisolone (methylprednisolone sodium succinate) 40mg - adrenals

Canada - English - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 125mg - methylprednisolone (methylprednisolone sodium succinate) 125mg - adrenals

Canada - English - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 500mg - methylprednisolone (methylprednisolone sodium succinate) 500mg - adrenals

Canada - English - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 1g - methylprednisolone (methylprednisolone sodium succinate) 1g - adrenals

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - prednisolone - gastro-resistant tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - prednisolone - gastro-resistant tablet - 1mg

Canada - English - Health Canada

teva canada limited - methylprednisolone (methylprednisolone sodium succinate) - powder for solution - 5g - methylprednisolone (methylprednisolone sodium succinate) 5g - adrenals

United States - English - NLM (National Library of Medicine)

par pharmaceutical - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone syrup (prednisolone oral solution usp) is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: sy

Israel - English - Ministry of Health

genmedix , israel - methylprednisolone as hemisuccinate - lyophilized powder for solution for injection or infusion - methylprednisolone as hemisuccinate 1 g/vial - methylprednisolone - methylprednisolone - methylprednisolone mylan is indicated to treat any condition in which iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.